Draganfly Inc. — FY2021 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2021. Although the request specifies 2021 Q4, this filing is an annual report and does not provide a clear standalone Q4 financial result. Unless stated otherwise, financial amounts below are in Canadian dollars and the consolidated statements follow IFRS.
Business context
Draganfly designs and manufactures unmanned aerial vehicles (UAVs) and provides engineering, drone-flight, training and related services. Its markets include public safety, government, agriculture, industrial inspection, mapping, energy and health applications. The company also acquired Vital Intelligence’s health/telehealth assets in March 2021.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $7.05 million | $4.36 million |
| Cost of sales | $4.41 million | $2.60 million |
| Gross profit | $2.64 million | $1.76 million |
| Gross margin | 37.5% | 40.3% |
| Operating expenses | $21.92 million | $10.25 million |
| Net loss | $16.20 million | $8.02 million |
| Basic and diluted loss per share | $0.59 | $0.48 |
| Cash and cash equivalents at year-end | $23.08 million | $1.98 million |
| Current assets / current liabilities | $33.56 million / $6.72 million | $4.36 million / $3.15 million |
| Total liabilities | $7.19 million | $3.25 million |
Revenue comprised product sales of $5.10 million, drone services of $1.30 million and other engineering/services revenue of $0.65 million. Operating cash flow was negative $22.00 million, compared with negative $5.13 million in 2020. Investing activities used $3.31 million; financing activities provided $46.27 million, principally from equity issuance and warrant and option exercises. Year-end working capital was approximately $26.84 million.
Reported loans payable were $93,317; lease liabilities were $489,123. The separate $5.56 million derivative liability primarily related to warrants and contingent consideration, rather than conventional borrowings. The company had no dividend history and said it did not expect to pay dividends in the foreseeable future.
Changes versus the prior year
- Revenue increased 61.7%, driven mainly by product sales, which rose from $3.09 million to $5.10 million. Service revenue was broadly flat excluding drone services, which increased.
- Gross profit rose, but gross margin declined by about 2.8 percentage points. Operating expenses more than doubled, with notable increases in insurance, office and miscellaneous expenses, professional fees, share-based payments and wages.
- Net loss approximately doubled. Results included a $4.58 million goodwill impairment and an $891,471 write-off of notes receivable. A $8.15 million gain from the change in fair value of derivative liabilities partly offset expenses; this was a fair-value accounting item, not operating revenue.
- Cash rose substantially following financing. The 2021 statements report $44.26 million of proceeds from share issuance, before $3.81 million of share-issue costs, plus proceeds from warrant and option exercises. The U.S. public offering generated approximately $17.98 million net proceeds, of which about $9.5 million had been used by year-end.
- Shares outstanding increased materially: 33.17 million at December 31, 2021, compared with 17.22 million at December 31, 2020. The filing reports 33.20 million outstanding as of March 28, 2022.
Outlook, commentary and risks
Management’s stated strategy is to grow through new products, industry-specific solutions, customer expansion and selective acquisitions. The filing provides no quantified revenue, earnings or cash-flow guidance. It describes substantial ongoing investment needs and says the company has a history of losses; it cautions that present revenues do not support operations and that inability to access capital could threaten its ability to continue as a going concern.
- Commercial agreements and execution: Disclosed opportunities include a Digital Dream Labs binding letter agreement described as a minimum $9 million manufacturing arrangement, with delivery expected to begin in 2022; the filing says a definitive agreement was not assured. Valqari’s initial manufacturing phase included at least $400,000 of services. Coldchain phase one was valued at US$125,000; a phase-two purchase commitment was subject to further negotiation and extension. These announcements should not be treated as fully realized or guaranteed revenue.
- Acquisition and valuation items: Vital contributed $115,369 of revenue and a $203,231 net loss from acquisition through year-end. The company impaired $4.58 million of goodwill, leaving $5.94 million of goodwill on the balance sheet. Management identified growth and discount-rate assumptions as particularly sensitive.
- Liquidity and working capital: Cash was $23.08 million at year-end, but operating cash use was $22.00 million. Prepaids increased to $5.49 million, including $2.94 million of prepaid insurance and $1.64 million of prepaid marketing services. Assess cash runway and the timing and recoverability of these balances.
- Operating and market risks: The filing highlights early-stage market adoption, competition, evolving Canadian and U.S. drone rules and permit requirements, dependence on a limited supplier base, product safety and liability, cybersecurity, and the need for future financing. It also cites pandemic-related supply-chain and labor uncertainty, inflation and Russia-Ukraine conflict-related market risks. Management reported minimal operational and supply-chain disruption to date, but could not rule out future impacts.
- Accounting and governance: U.S.-dollar warrants are recorded as liabilities and remeasured through earnings, creating potential volatility. Disclosure controls were assessed as effective, but the filing did not include management’s ICFR assessment or an auditor attestation because of a transition period for newly public companies. The auditor issued an unqualified opinion on the IFRS financial statements.
The filing also discloses a historical 1998 Alberta Stock Exchange settlement involving CEO Cameron Chell, including a $25,000 fine and restrictions that have since expired. It reports no material legal proceedings meeting the stated threshold for the most recently completed financial year.
Most important facts for investors to verify
- Review the complete MD&A and notes for cash-flow forecasts, funding needs and any going-concern assessment; the filing’s summary disclosures do not provide a quantified runway forecast.
- Confirm the status, definitive terms, customer funding and delivery performance of the announced manufacturing and service agreements, particularly the Digital Dream Labs arrangement and Coldchain phases.
- Assess the assumptions behind Vital’s goodwill impairment, remaining goodwill and contingent consideration, and the collectability of notes receivable, including the $891,471 write-off.
- Reconcile the unusually large derivative fair-value gain, outstanding warrants and potential dilution from warrants, options, RSUs and the rolling equity compensation plan.
- Track operating cash burn, gross-margin trends, elevated expenses and the composition and use of year-end prepaids; distinguish financing proceeds from recurring operating cash generation.